β
Transdermal
πΉ Transdermal medications are absorbed through the skin directly into the systemic circulation.
πΉ This route bypasses the gastrointestinal tract and initial hepatic processing.
πΉ The medication therefore avoids significant first-pass metabolism before reaching systemic circulation.
πΉ Transdermal administration can provide slow and sustained medication delivery over an extended period.
πΉ Common examples include nitroglycerin, nicotine, fentanyl, and hormone patches.
πΉ The effectiveness of this route depends partly on the medication's ability to penetrate the skin barrier.
πΉ Avoiding first-pass metabolism can improve the bioavailability of medications that would otherwise be extensively metabolized by the liver.
πΉ Therefore, the transdermal route is an appropriate route for avoiding first-pass metabolism.
β
Intranasal
πΉ Intranasal medications are absorbed through the highly vascular nasal mucosa.
πΉ Absorption allows medication to enter the systemic circulation without first passing through the gastrointestinal tract.
πΉ This route therefore avoids significant hepatic first-pass metabolism.
πΉ The nasal mucosa has an extensive blood supply that can allow rapid medication absorption.
πΉ Intranasal administration can be useful when a rapid therapeutic effect is desired.
πΉ Examples of systemically acting intranasal medications include naloxone and desmopressin.
πΉ Absorption can vary depending on nasal congestion, mucosal integrity, and the medication formulation.
πΉ Therefore, the intranasal route can bypass first-pass metabolism.
β
Intravaginal
πΉ Intravaginal medications can be absorbed through the vascular vaginal mucosa.
πΉ Medication absorbed through this mucosa does not initially travel through the portal circulation in the same way as swallowed medication.
πΉ This route therefore largely avoids hepatic first-pass metabolism.
πΉ Vaginal medications can produce either local or systemic effects, depending on the medication and formulation.
πΉ The vaginal mucosa provides an effective absorptive surface for certain hormones and other medications.
πΉ Systemic absorption can occur without requiring passage through the stomach and intestines.
πΉ Avoidance of extensive first-pass metabolism can increase the medication's systemic availability.
πΉ Therefore, the intravaginal route is included among routes that bypass first-pass metabolism.
β
Subcutaneous
πΉ Subcutaneous medications are injected into tissue beneath the skin.
πΉ The medication is absorbed from the subcutaneous tissue into the systemic circulation.
πΉ This route completely bypasses absorption through the gastrointestinal tract.
πΉ It also avoids initial delivery through the hepatic portal circulation.
πΉ Subcutaneous administration therefore avoids first-pass hepatic metabolism.
πΉ Common examples include insulin and heparin.
πΉ Absorption is generally slower than intravenous administration because it depends on local tissue blood flow.
πΉ Therefore, the subcutaneous route avoids first-pass metabolism.